相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。How Long Have I Got? Estimating Typical, Best-Case, and Worst-Case Scenarios for Patients Starting First-Line Chemotherapy for Metastatic Breast Cancer: A Systematic Review of Recent Randomized Trials
Belinda E. Kiely et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
Kimberly L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Lapatinib Plus Capecitabine in Women with HER-2-Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial
David Cameron et al.
ONCOLOGIST (2010)
Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer
Rupert Bartsch et al.
BMC CANCER (2009)
Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
David Cameron et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer
Rupert Bartsch et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Retrospective Evaluation of Clinical Outcomes in Patients with HER2-Positive Advanced Breast Cancer Progressing on Trastuzumab-Based Therapy in the Pre-Lapatinib Era
Filippo Montemurro et al.
CLINICAL BREAST CANCER (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
An overview of prognostic factors for long-term survivors of breast cancer
Isabelle Soerjomataram et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer
Rupert Bartsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)
BC Pestalozzi et al.
ANNALS OF ONCOLOGY (2006)
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
Rita Nahta et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study
R Bartsch et al.
BMC CANCER (2006)
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression
D Tripathy et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
Prognostic and predictive factors in breast cancer
NJ Bundred
CANCER TREATMENT REVIEWS (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
分享论文
